Clinical Trial Update: Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC Study

View source ↗

Summary

The OPBC-11/MACRONAC clinical trial investigates whether axillary lymph node dissection is appropriate for residual macrometastases after neoadjuvant chemothera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Breast Cancer | Status: ACTIVE_NOT_RECRUITING